Twist Bioscience revenue and financials
$201.70Change from previous close: +6.91%Absolute change: +$13.03
In the fiscal year ended September 2025, Twist Bioscience reported revenue of $376.57M (+20.32% year over year). The net loss was $77.67M.
Fiscal year ending in September. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +20.32%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- -20.6%
- FY to Sep 2024: -66.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 | FY to Sep 2021 | FY to Sep 2020 | FY to Sep 2019 | FY to Sep 2018 | FY to Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 377 | 313 | 245 | 204 | 132 | 90.1 | 54.4 | 25.4 | 10.8 |
| Cost of revenue | 186 | 180 | 155 | 119 | 80.6 | 61.4 | 47.4 | 32.2 | 24.0 |
| Gross profit | 191 | 133 | 89.7 | 84.2 | — | — | — | — | — |
| Selling, general and administrative | 247 | 218 | 190 | 213 | — | — | — | — | — |
| Research and development | 80.3 | 90.9 | 107 | 120 | 69.1 | 43.0 | 35.7 | 20.3 | 19.2 |
| Operating income | -136 | -221 | -217 | -235 | -153 | -140 | -109 | -70.6 | -58.5 |
| EBIT | -136 | -176 | -207 | -228 | — | — | — | — | — |
| EBITDA | -111 | -144 | -178 | -212 | — | — | — | — | — |
| Interest expense | — | 0.0 | 0.0 | 0.1 | 0.4 | 0.8 | 1.3 | 1.3 | 0.9 |
| Pre-tax income | -77.0 | -208 | -203 | -228 | — | — | — | — | — |
| Income tax | 0.7 | 0.6 | 1.2 | -10.4 | -1.9 | 0.4 | 0.3 | 0.2 | 0.3 |
| Net income | -77.7 | -209 | -205 | -218 | -152 | -140 | -108 | -71.2 | -59.3 |
| Net income to common shareholders | -77.7 | -209 | -205 | -218 | — | — | — | — | — |
| Basic EPS | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | — | — | — |
| Diluted EPS | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | — | — | — |
| Average shares (basic) | 59.8 | 58.0 | 56.9 | 53.9 | — | — | — | — | — |
| Average shares (diluted) | 59.8 | 58.0 | 56.9 | 53.9 | 48.3 | 39.2 | — | — | — |